SCHEMBL25322740

SCHEMBL25322740

Cc1cc(C2CCC(C)CN2C(=O)OC(C)(C)C)n(C)n1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 5/20 0.34
WDR77 Q9BQA1 2/20 0.34
NPSR1 Q6W5P4 2/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
GPR119 Q8TDV5 1/20 0.32
MAPT P10636 1/20 0.32
GRM5 P41594 2/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322738 1.00 PRMT5 (0.34) PRMT5WDR77NPSR1LMNACYP1A2
SCHEMBL29082018 0.83 ALDH1A1 (0.42) PRMT5WDR77NPSR1LMNAMAPT
SCHEMBL25321795 0.83 PRMT5 (0.37) PRMT5WDR77LMNAALDH1A1L3MBTL1
SCHEMBL25321799 0.83 PRMT5 (0.37) PRMT5WDR77LMNAALDH1A1L3MBTL1
SCHEMBL24363821 0.80 PRMT5 (0.41) PRMT5WDR77LMNAGPR119ALDH1A1
SCHEMBL25323476 0.80 PRMT5 (0.40) PRMT5WDR77ALDH1A1TSHR
SCHEMBL25323471 0.80 PRMT5 (0.40) PRMT5WDR77ALDH1A1TSHR
SCHEMBL25321958 0.76 LMNA (0.36) PRMT5WDR77LMNAPOLBMAPT
SCHEMBL18403342 0.75 SLC34A1 (0.44) GPR119MAPTALDH1A1
SCHEMBL24365995 0.74 PRMT5 (0.47) PRMT5WDR77LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN PRMT5 562/4885WDR77 1925/4885NPSR1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.